

Contents

List of contributing authors — xiii

Introduction — 1

Nicole Frankenberg-Dinkel

1 History of biotechnology and classical applications in food biotechnology — 3

1.1 History of food biotechnology (a brief overview) — 3

1.1.1 Bread-baking in ancient Egypt — 4

1.1.2 Ancient beer brewing — 4

1.1.3 Winemaking (vinification) — 4

1.1.4 The first description of bacteria and yeast — 5

1.2 A work horse of food biotechnology: Yeast — 5

1.2.1 Glycolysis — 7

1.3 Alcohol fermentation by yeast — 7

1.3.1 Winemaking — 10

1.3.2 Beer brewing — 12

1.3.3 Side products during yeast fermentation — 14

1.4 Alcohol fermentation by bacteria — 15

1.5 Lactic acid fermentation — 16

1.5.1 Yoghurt — 16

1.5.2 Kefir — 19

1.5.3 Cheese — 20

1.5.4 Sourdough — 21

1.5.5 Sauerkraut — 22

1.5.6 Malolactic fermentation by lactic acid bacteria during winemaking — 22

Robert Kourist and Sarah Gaßmeyer

2 Biocatalysis and enzyme engineering — 25

2.1 Introduction to biocatalysis — 25

2.1.1 Lipases – robust enzymes for industrial biotechnology — 27

2.1.2 Regioselective enzymatic interesterification of lipids — 30

2.1.3 Enantioselectivity of enzymes — 32

2.1.4 Lipase-catalyzed kinetic resolution of alcohols — 34

2.1.5 Lipase-catalyzed kinetic resolution of amines — 35

2.1.6 Transaminase-catalyzed asymmetric synthesis of amines — 36

2.2 Introduction to enzyme engineering — 36

2.2.1 Structure-function relationships — 38

2.2.2 Enzyme engineering — 39

- 2.2.3 Protein engineering of a biocatalyst for the synthesis of the blockbuster drug Sitagliptin — 41

Mathias Lübben and Raphael Gasper

3 Prokaryotes as protein production facilities — 47

- 3.1 General considerations of prokaryotic protein production — 47
- 3.1.1 Purpose of the protein – homologous vs. heterologous expression strategies — 47
- 3.1.2 Choice of a suitable expression host — 51
- 3.1.3 Adjustment of growth conditions — 52
- 3.1.4 Choice of a suitable vector system and appropriate mode of expression (control of gene dosis) — 54
- 3.1.5 Multicistronic gene expression — 54
- 3.1.6 Measures in case of toxic target genes — 54
- 3.1.7 Tagging of expressed protein to meet special needs — 55
- 3.1.8 Handling of inclusion bodies — 56
- 3.1.9 Protein stability – folding aided by chaperones — 57
- 3.1.10 Membrane insertion and folding of membrane proteins in prokaryotes — 58
- 3.2 *Escherichia coli* – the most popular host for protein production — 61
- 3.2.1 Induced recombinant gene expression — 66
- 3.2.2 Expression conditions — 70
- 3.2.3 *E. coli* strains used for high-level protein expression — 72
- 3.2.4 Peptide and protein tags used for protein localization or affinity purification in *E. coli* — 74
- 3.3 Other prokaryotic organisms for protein production — 77
- 3.3.1 *Rhodobacter sphaeroides* and *capsulatus* — 77
- 3.3.2 *Bacillus subtilis* and other *Bacilli* — 79
- 3.3.3 *Lactococcus lactis* — 81
- 3.3.4 *Halobacterium salinarum* — 82

Ulrich Kück and Ines Teichert

4 Fungal biotechnology — 89

- 4.1 Fungal biology — 90
- 4.2 Food biotechnology — 93
- 4.3 Primary metabolism — 97
- 4.3.1 Organic acids — 97
- 4.3.2 Technical enzymes — 101
- 4.3.3 Biotransformation — 105
- 4.4 Secondary metabolism — 107
- 4.5 Recombinant technologies — 114

- 4.5.1 Generation of recombinant fungal strains — 114
- 4.5.2 Recombinant fungal products — 118

Franz Narberhaus

- 5 Blue biotechnology — 123**
 - 5.1 The challenges of marine life — 123
 - 5.2 The census of marine life and metagenome projects — 123
 - 5.3 Food from the sea — 126
 - 5.3.1 Aquaculture — 126
 - 5.3.2 Genetically modified (GM) fish — 128
 - 5.4 Tools for molecular biology from the ocean — 132
 - 5.5 Drugs from the sea — 134
 - 5.6 Non-medical marine products — 136
 - 5.6.1 Enzymes — 136
 - 5.6.2 Other marine products — 137
 - 5.7 The prospects of blue biotechnology — 139

Marc Nowaczyk, Sascha Rexroth and Matthias Rögner

- 6 Biotechnological potential of cyanobacteria — 141**
 - 6.1 Optimization of the “chassis” and principal methods — 144
 - 6.1.1 Selection of appropriate cyanobacterial strains — 144
 - 6.1.2 Genetic tools for metabolic engineering of cyanobacteria — 146
 - 6.1.3 Determination of photosynthetic parameters & efficiency — 148
 - 6.1.4 Reduction of antenna size and increase of electron transport — 149
 - 6.2 Examples for cyanobacterial biotech products — 150
 - 6.2.1 Non C-based: Photosynthetic biohydrogen production — 150
 - 6.2.2 C-based biofuels and bulk chemicals — 152
 - 6.3 Strategies to design mass cultivation in photobioreactors — 155
 - 6.3.1 Photobioreactor Design — 155
 - 6.3.2 Downstream processing — 157
 - 6.3.3 Scale up — 158
 - 6.4 Outlook – future potential of cyanobacteria — 161

Thomas Happe and Anja Hemschemeier

- 7 Eukaryotic microalgae in biotechnological applications — 165**
 - 7.1 Biotechnological exploitation of oxygenic photosynthesis — 166
 - 7.1.1 Principles — 166
 - 7.1.2 Utilization — 169
 - 7.1.3 Economics — 169
 - 7.2 Established applications — 172
 - 7.2.1 Microalgal biomass — 173
 - 7.2.2 β -carotene and astaxanthin — 176

7.2.3	Polyunsaturated fatty acids (PUFAs) —	180
7.3	Potential future applications —	183
7.3.1	Triacylglycerols – Biodiesel —	183
7.3.2	Photobiological generation of molecular hydrogen (H ₂) —	184
7.4	Genetic modification —	186
7.4.1	Pathway engineering —	187
7.4.2	Expression of transgenes —	190

Ansgar Poetsch and Andreas Harst

8	Strain design and -omics technologies —	197
8.1	Classical methods of strain optimization —	197
8.2	Genome engineering —	200
8.3	Engineering metabolism: from enzymes to metabolic networks —	203
8.4	-Omics technologies for strain characterization and optimization —	207
8.5	Synthetic biology's impact on strain design —	210
8.6	The amino acid producer <i>C. glutamicum</i> as an example for strain engineering —	212

Markus Piotrowski

9	Biotechnology of higher plants —	219
9.1	Conventional breeding techniques —	219
9.1.1	Traditional breeding —	220
9.1.2	Breeding techniques using biotechnology —	222
9.2	Regeneration of whole plants from plant tissue or single cells —	230
9.3	Transgenic breeding —	231
9.3.1	Direct gene transfer methods —	231
9.3.2	<i>Agrobacterium</i> -mediated transformation —	234
9.3.3	Transformation of plastids —	237
9.3.4	Architecture of the transgene construct —	237
9.3.5	Marker genes —	240
9.3.6	Silencing genes in transgenic plants —	244
9.4	Main traits in commercialized-transgenic plants —	246
9.4.1	Input traits and output traits —	246
9.4.2	Herbicide resistance —	246
9.4.3	Herbivore resistance using Bt toxin —	249
9.4.4	Other traits —	250
9.5	Current status of commercialized transgenic plants —	258

- 9.6 Plants as producers of pharmaceuticals — 259
- 9.6.1 Pharmaceuticals isolated from plants — 259
- 9.6.2 Plants as producers of proteinaceous pharmaceuticals — 262

Stefan Wiese, Dennis Stern and Alice Klausmeyer

- 10 Transgenic animals — 267**
 - 10.1 History of transgenic animals — 267
 - 10.2 Isolation of fertilized eggs, morulae and blastocysts — 269
 - 10.3 Tetraploid embryos — 272
 - 10.4 Pronucleus injection of fertilized eggs — 273
 - 10.5 Embryonic stem cells and induced pluripotent stem cells — 275
 - 10.6 Strategies for gene transfer — 278
 - 10.6.1 Transgene expression — 278
 - 10.6.2 Insertion mutagenesis — 278
 - 10.6.3 Antisense-RNA — 279
 - 10.6.4 Dominant-negative mutation — 279
 - 10.6.5 Homologous recombination — 279
 - 10.6.6 Genetic ablation of specific cell types — 280

Andreas Faissner, Jacqueline Reinhard and Ursula Theocharidis

- 11 Stem cell biology and applications in neuroscience — 285**
 - 11.1 Embryonic stem cells — 285
 - 11.1.1 Fertilized egg cell and totipotency — 285
 - 11.1.2 *In vitro* fertilization and ES-lines — 286
 - 11.1.3 Tissue-specific and organ-specific stem cells — 288
 - 11.1.4 General features of stem cells — 288
 - 11.1.5 Adult stem cells — 289
 - 11.1.6 The stem cell niche — 290
 - 11.2 Reprogramming stem cells — 291
 - 11.2.1 Generation of distinct cell populations from human embryonic stem cells — 291
 - 11.2.2 Human embryonic stem cells as a tool for repair — 291
 - 11.2.3 Concepts for the reprogramming of hESCs — 292
 - 11.2.4 The discovery of induced pluripotency — 293
 - 11.2.5 Induced pluripotency as a novel, broadly applicable experimental strategy — 293
 - 11.2.6 Applications of induced pluripotent stem cells — 294
 - 11.2.7 Themes of regenerative medicine — 296
 - 11.2.8 The cardiovascular system — 296
 - 11.3 Direct conversion as an alternative to iPS cells — 297
 - 11.3.1 Induced cells — 297
 - 11.3.2 Epigenetic landscapes of induced cells — 298

11.4	Stem cell technology and standardization —	299
11.4.1	Generation of hiPSCs —	299
11.4.2	Technical challenges of stem cell applications —	299
11.5	Stem cells of the nervous system —	301
11.5.1	The radial glia cell as stem cell of the nervous system —	301
11.5.2	Adult neural stem cells —	303
11.5.3	Applications of stem cells to neural repair —	305
11.6	Development and stem cells of the eye —	306
11.6.1	Development of the neural retina – Retinogenesis —	306
11.6.2	Stem/progenitor cell populations of the eye and neural retina —	308
11.6.3	Müller glia as potential stem/progenitor cells —	308
11.6.4	Stem cell based therapies of chronic eye diseases —	310

Olivia A. Masseck, Katharina Spoida and Stefan Herlitze

12	Optogenetics —	315
12.1	Early developments —	315
12.2	Fast on and off switches —	322
12.2.1	Depolarization of neurons: Channelrhodopsin —	322
12.2.2	Hyperpolarization of neurons: Halorhodopsin, Arch and MAC —	323
12.3	Modulation of intracellular G-protein signals —	327
12.3.1	The $G_{i/o}$ pathway —	328
12.3.1	The G_q pathway —	330
12.3.3	The G_s pathway —	331
12.4	Regulation of Protein-Protein interactions —	334
12.4.1	Phytochromes —	334
12.4.2	Phototropins —	336
12.4.3	Cryptochromes —	338
12.5	Therapeutic applications —	339
12.5.1	Delivery of optogenetic tools to intact systems —	339
12.5.2	Cell-type specificity —	342
12.5.3	The cure of blindness: Retinitis pigmentosa —	342
12.5.4	Application to other diseases —	344

Hermann Lübbert

13	Drug development and registration —	349
13.1	Historical background —	350
13.2	Drug discovery —	352
13.2.1	Drug targets —	352
13.2.2	Screening and design —	353
13.3	Drug development —	355
13.3.1	Pre-clinical phase —	356

13.3.2	Clinical phase —	357
13.4	Statistical analysis —	362
13.4.1	Statistical power —	362
13.4.2	Statistical and epidemiological analysis plan —	362
13.5	Pharmacovigilance —	363
13.6	The quality management system —	364
13.7	The drug approval process —	366
13.8	The common technical document —	368

Axel Mosig

14	Bioinformatics —	375
14.1	Introduction —	376
14.2	Genome sequencing —	378
14.2.1	Shotgun sequencing —	378
14.2.2	Genome annotation —	381
14.2.3	Partial genome sequencing and resequencing —	384
14.3	Comparative genomics —	386
14.3.1	Sequence alignments —	386
14.3.2	Homology search —	388
14.3.3	Whole-Genome Comparison —	394
14.4	Transcriptome analysis and non-coding RNAs —	396
14.4.1	Non-coding RNA secondary structure —	396
14.4.2	Homology patterns of non-coding RNAs —	401
14.4.3	Gene expression analysis —	402
14.5	Other topics in bioinformatics biotechnology —	405
14.5.1	Evolutionary bioinformatics —	405
14.5.2	Regulatory genomics and systems biology —	406
14.5.3	Proteomics data analysis —	406
14.5.4	Bioimage informatics —	407

Glossary — 411

Index — 429